Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERICLES atezolizumab with or without radiotherapy in penile cancer
2018-000603-17Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in penile cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Progression-free survival at 1 year. Started Jun 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
penile cancer
Beyond the preview
Go deeper on 2018-000603-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000603-17.